ArticleThe American journal of pathology2010
The immunoconjugate "icon" targets aberrantly expressed endothelial tissue factor causing regression of endometriosis.
Article in The American journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 71 citations in OpenAlex.
- L-ICON3 Suppresses Endometriosis in a Murine Model.Journal of molecular medicine (Berlin, Germany) · 2026Article
- WERF Endometriosis Phenome and Biobanking Harmonisation Project for Experimental Models in Endometriosis Research (EPHect-EM-Heterologous): heterologous rodent models.Molecular human reproduction · 2025Review
- New Therapeutics in Endometriosis: A Review of Hormonal, Non-Hormonal, and Non-Coding RNA Treatments.International journal of molecular sciences · 2021Review
- Multi-omics analysis reveals the interaction between the complement system and the coagulation cascade in the development of endometriosis.Scientific reports · 2021Article
- Intramuscular Expression of Plasmid-Encoded FVII-Fc Immunoconjugate for Tumor Immunotherapy by Targeting Tumoral Blood Vessels and Cells.Frontiers in oncology · 2021Article
- Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer.Molecules (Basel, Switzerland) · 2020Review
- Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.Scientific reports · 2020Article
- The Microenvironment of Tongue Cancer.Advances in experimental medicine and biology · 2020Review
- Is there a correlation between inflammatory markers and coagulation parameters in women with advanced ovarian endometriosis?BMC women's health · 2019Article
- Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.Cancer immunology research · 2018Article
- Rodent Models of Experimental Endometriosis: Identifying Mechanisms of Disease and Therapeutic Targets.Current women's health reviews · 2018Review
- Therapeutic Antibody-Like Immunoconjugates against Tissue Factor with the Potential to Treat Angiogenesis-Dependent as Well as Macrophage-Associated Human Diseases.Antibodies (Basel, Switzerland) · 2018Article
- Therapeutically Targeting the Inflammasome Product in a Chimeric Model of Endometriosis-Related Surgical Adhesions.Reproductive sciences (Thousand Oaks, Calif.) · 2017Article
- Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy.Angiogenesis · 2017Article
- The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding.Human reproduction update · 2016Review
- Tissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes.Biomarkers in cancer · 2015Review
- Effects of simvastatin on retinoic acid system in primary human endometrial stromal cells and in a chimeric model of human endometriosis.The Journal of clinical endocrinology and metabolism · 2013Article
- Dietary fish oil supplementation inhibits formation of endometriosis-associated adhesions in a chimeric mouse model.Fertility and sterility · 2013Article
- Molecular blockade of angiogenic factors: A new therapeutic tool for the treatment of abnormal uterine bleeding.Journal of mid-life health · 2013Article
- Induction of endometriosis alters the peripheral and endometrial regulatory T cell population in the non-human primate.Human reproduction (Oxford, England) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Endometriosis is a major cause of chronic pain, infertility, medical and surgical interventions, and health care expenditures. Tissue factor (TF), the primary initiator of coagulation and a modulator of angiogenesis, is not normally expressed by the endothelium; however, prior studies have demonstrated that both blood vessels in solid tumors and choroidal tissue in macular degeneration express endothelial TF. The present study describes the anomalous expression of TF by endothelial cells in endometriotic lesions. The immunoconjugate molecule (Icon), which binds with high affinity and specificity to this aberrant endothelial TF, has been shown to induce a cytolytic immune response that eradicates tumor and choroidal blood vessels. Using an athymic mouse model of endometriosis, we now report that Icon largely destroys endometriotic implants by vascular disruption without apparent toxicity, reduced fertility, or subsequent teratogenic effects. Unlike antiangiogenic treatments that can only target developing angiogenesis, Icon eliminates pre-existing pathological vessels. Thus, Icon could serve as a novel, nontoxic, fertility-preserving, and effective treatment for endometriosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.